e-learning
resources
European Respiratory Review
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
When to start and when to stop antifibrotic therapies
Sebastiano Emanuele Torrisi, Mauro Pavone, Ada Vancheri, Carlo Vancheri
Source:
Eur Respir Rev, 26 (145) 170053; 10.1183/16000617.0053-2017
Journal Issue:
September
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sebastiano Emanuele Torrisi, Mauro Pavone, Ada Vancheri, Carlo Vancheri. When to start and when to stop antifibrotic therapies. Eur Respir Rev, 26 (145) 170053; 10.1183/16000617.0053-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies
Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy
Year: 2017
How to stop LC-fILD progression: an overview of modern therapeutic strategies
Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists
Year: 2021
How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach
Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists
Year: 2021
Timely start of HFNC treatment is beneficial for the outcome in COVID-19
Source: Virtual Congress 2021 – Non-invasive respiratory support in COVID-19
Year: 2021
Alternative immunosuppressive strategies
Source: ERS Course 2016
Year: 2016
GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis
Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Year: 2018
Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy?
Source: Eur Respir J 2004; 24: 1-2
Year: 2004
Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment
Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021
Year: 2021
Targeting targeted therapies: more choices and the best sequences
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018
Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes
Source: Virtual Congress 2021 – Wheezing illnesses along the life span
Year: 2021
Do we have any alternative therapeutic option beyond antibiotics?
Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions
Year: 2021
Old and new strategies in induction therapy
Source: School Course 2012 - Lung Transplantation
Year: 2012
Next generation of anti-inflammatory therapy for COPD?
Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017
Year: 2017
How to manage side-effects of targeted therapies?
Source: Annual Congress 2010 - PG7 Postgraduate Course: How to manage treatment complications of lung cancer
Year: 2010
Effect of sildenafil add-on to antifibrotic treatment in IPF patients
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Impact of antifibrotic drugs in lung transplantation
Source: International Congress 2019 – Lung transplantation: from basic science to clinical outcomes
Year: 2019
What influences patient choice of antifibrotic treatment in IPF?
Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept